Delving into the Latest Updates on Daito Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Immune System Diseases	1
Infectious Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

COXs(Cyclooxygenases)	1
DDC x DRDs	1

主要研究目的评价中国健康成年试验参与者空腹条件下单次单剂量口服伏格列波糖口崩片受试制剂0.6mg【规格：0.2mg，申办者：大桐制药（中国）有限责任公司】和参比制剂0.6mg（商品名：Basen®，规格：0.2mg，持证商：武田テバ薬品株式会社）后的药效动力学特点和生物等效性。次要研究目的研究伏格列波糖口崩片受试制剂0.6mg（规格：0.2mg）和参比制剂0.6mg（商品名：Basen®，规格：0.2mg）在中国健康成年试验参与者中的安全性。

[Translation]

Primary Objective: To evaluate the pharmacokinetic characteristics and bioequivalence of a single, fasting oral dose of voglibose orally disintegrating tablets (test formulation 0.6 mg [strength: 0.2 mg, sponsor: Daitung Pharmaceutical (China) Co., Ltd.] and reference formulation 0.6 mg (trade name: Basen®, strength: 0.2 mg, licensee: Takeda Teba Pharmaceutical Co., Ltd.) in healthy adult participants in China. Secondary Objective: To investigate the safety of voglibose orally disintegrating tablets (test formulation 0.6 mg [strength: 0.2 mg] and reference formulation 0.6 mg [trade name: Basen®, strength: 0.2 mg] in healthy adult participants in China.

Start Date20 Jul 2026

Sponsor / Collaborator

Daito Pharmaceutical (CHINA) Co., Ltd.

CTR20261723

/ Active, not recruitingNot Applicable

别嘌醇片生物等效性试验

[Translation] Bioequivalence study of allopurinol tablets

主要研究目的评价中国健康成年试验参与者空腹及餐后条件下单次单剂量口服别嘌醇片受试制剂（规格：0.1g，申办者：大桐制药（中国）有限责任公司）和参比制剂（商品名：Zyloric®，规格：100mg，持证商：Aspen Pharma Trading Limited）后的药代动力学特点和生物等效性。次要研究目的研究别嘌醇片受试制剂（规格：0.1g）和参比制剂（商品名：Zyloric®，规格：100mg）在中国健康成年试验参与者中的安全性。

[Translation]

Primary Objective: To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of allopurinol tablets (0.1 g, sponsor: Datong Pharmaceutical (China) Co., Ltd.) and reference formulation (Zyloric®, 100 mg, licensee: Aspen Pharma Trading Limited) under fasting and postprandial conditions in healthy adult Chinese participants. Secondary Objective: To investigate the safety of allopurinol tablets (0.1 g, reference formulation: Zyloric®, 100 mg) in healthy adult Chinese participants.

Start Date18 May 2026

Sponsor / Collaborator

Daito Pharmaceutical (CHINA) Co., Ltd.

CTR20261521

/ CompletedNot Applicable

评价盐酸罗匹尼罗片在中国成年健康试验参与者中的一项单中心、随机、开放、空腹单次给药、两制剂、两周期、双交叉的生物等效性研究

[Translation] A single-center, randomized, open-label, fasting, single-dose, two-formulation, two-period, two-crossover bioequivalence study of ropinirole hydrochloride tablets in healthy adult participants in China.

主要研究目的评价空腹状态下受试制剂和参比制剂在中国成年健康试验参与者中的生物等效性。次要目的：评价空腹状态下受试制剂和参比制剂在中国健康成年试验参与者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test formulation and the reference formulation in healthy adult participants in China under fasting conditions. Secondary objective: To evaluate the safety of the test formulation and the reference formulation in healthy adult participants in China under fasting conditions.

Start Date05 May 2026

Sponsor / Collaborator

Daito Pharmaceutical (CHINA) Co., Ltd.

100 Clinical Results associated with Daito Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Daito Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Daito Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Daito Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Sep 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Approved

Login to view more data